Identification and Preliminary Characterization of Novel Small Molecules That Inhibit Growth of Human Lung Adenocarcinoma Cells

Abstract

Drug treatment for human lung cancers remains unsatisfactory, despite the identification of many potential therapeutic targets (such as mutant KRAS protein) and the approval of agents that inhibit the tyrosine kinase activity of mutant epidermal growth factor receptor (EGFR). To seek new therapeutic strategies against lung tumors, the authors have screened 189,290 small molecules for their ability to retard growth of human lung adenocarcinoma cell lines, which harbor mutations in EGFR or KRAS. Four candidates that are structurally different from common tyrosine kinase inhibitors were selected for further study. The authors describe one small molecule (designated lung cancer screen—1 [LCS-1]) in detail here. Identification of the targets of LCS-1 and other growth inhibitors found in this screen may help to develop new agents for the treatment of lung adenocarcinomas, including those driven by mutant EGFR and KRAS. (Journal of Biomolecular Screening 2009: 1176-1184)

Keywords

high-throughput drug screen lung cancer EGFR KRAS

References

Jemal A. , Siegel R. , Ward E. , Hao Y. , Xu J. , Murray T. , et al: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.

Pao W. , Miller VA : Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.

Lynch TJ , Bell DW , Sordella R. , Gurubhagavatula S. , Okimoto RA , Brannigan BW , et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.

Paez JG , Janne PA , Lee JC , Tracy S. , Greulich H. , Gabriel S. , et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.

Pao W. , Miller V. , Zakowski M. , Doherty J. , Politi K. , Sarkaria I. , et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 ;101:13306-13311.

Kobayashi S. , Boggon TJ , Dayaram T. , Janne PA , Kocher O. , Meyerson M. , et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 ;352:786-792.

Pao W. , Miller VA , Politi KA , Riely GJ , Somwar R. , Zakowski MF , et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.

Bean J. , Brennan C. , Shih JY , Riely G. , Viale A. , Wang L. , et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib . Proc Natl Acad Sci USA 2007;104:20932-20937.

Engelman JA , Zejnullahu K. , Mitsudomi T. , Song Y. , Hyland C. , Park JO , et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 ;316:1039-1043.

10.

Rodenhuis S. , Slebos RJ : The ras oncogenes in human lung cancer. Am Rev Respir Dis 1990;142:S27-S30.

11.

Suzuki Y. , Orita M. , Shiraishi M. , Hayashi K. , Sekiya T. : Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990;5:1037-1043.

12.

Ding L. , Getz G. , Wheeler DA , Mardis ER , McLellan MD , Cibulskis K. , et al: Somatic mutations affect key pathways in lung adenocarcinoma . Nature 2008;455:1069-1075.

13.

Weir BA , Woo MS , Getz G. , Perner S. , Ding L. , Beroukhim R. , et al: Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898.

14.

Shum D. , Radu C. , Kim E. , Cajuste M. , Shao Y. , Seshan VE , et al: A high density assay format for the detection of novel cytotoxic agents in large chemical libraries. J Enzyme Inhib Med Chem 2008;23:931-945.

15.

Antczak C. , Shum D. , Radu C. , Seshan VE , Djaballah H. : Development and validation of a high-density fluorescence polarization-based assay for the trypanosoma RNA triphosphatase TbCet1. Comb Chem High Throughput Screen 2009;12:258-268.

16.

Zhang JH , Chung TD , Oldenburg KR : A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.

17.

Sordella R. , Bell DW , Haber DA , Settleman J. : Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.

18.

Tracy S. , Mukohara T. , Hansen M. , Meyerson M. , Johnson BE , Janne PA : Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-7244.

19.

Ghose AK , Viswanadhan VN , Wendoloski JJ : A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery: 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1:55-68.

20.

Whitehurst AW , Bodemann BO , Cardenas J. , Ferguson D. , Girard L. , Peyton M. , et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-819.

21.

Wood LD , Parsons DW , Jones S. , Lin J. , Sjoblom T. , Leary RJ , et al: The genomic landscapes of human breast and colorectal cancers . Science 2007;318:1108-1113.

22.

Guha U. , Chaerkady R. , Marimuthu A. , Patterson AS , Kashyap MK , Harsha HC , et al: Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 2008;105:14112-14117.

23.

Rikova K. , Guo A. , Zeng Q. , Possemato A. , Yu J. , Haack H. , et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.

24.

Godl K. , Wissing J. , Kurtenbach A. , Habenberger P. , Blencke S. , Gutbrod H. , et al: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100: 15434-15439.

25.

Lamb J. , Crawford ED , Peck D. , Modell JW , Blat IC , Wrobel MJ , et al: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935.

26.

Yang WS , Stockwell BR : Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008;15:234-245.